SCHEMBL25952401

SCHEMBL25952401

COCOc1c(C)c(O)c(C(=O)/C=C/c2ccc(Cl)cc2)c(OC)c1C

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 2/20 0.59
▸ KCNA3 P22001 2/20 0.47
▸ MAOB P27338 5/20 0.45
▸ MAOA P21397 2/20 0.45
▸ PTGS2 P35354 1/20 0.44
▸ MAPT P10636 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ ABCG2 Q9UNQ0 3/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CXCL12 P48061 1/20 0.41
▸ CXCR4 P61073 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25429661 1.00 ABCB1 (0.59) ABCB1KCNA3MAOBMAOAPTGS2
SCHEMBL25952454 0.91 ABCB1 (0.61) ABCB1KCNA3MAOBMAOAMAPT
SCHEMBL25952507 0.91 ABCB1 (0.61) ABCB1KCNA3MAOBMAOAMAPT
SCHEMBL25339313 0.91 ABCB1 (0.61) ABCB1KCNA3MAOBMAOAMAPT
SCHEMBL25342585 0.90 ABCB1 (0.60) ABCB1KCNA3MAOBMAPTTDP1
SCHEMBL25339626 0.90 ABCB1 (0.60) ABCB1KCNA3MAOBMAOAMAPT
SCHEMBL25952463 0.90 ABCB1 (0.60) ABCB1KCNA3MAOBMAOAMAPT
SCHEMBL25952460 0.90 ABCB1 (0.60) ABCB1KCNA3MAOBMAPTTDP1
SCHEMBL25340266 0.89 ABCB1 (0.57) ABCB1KCNA3MAPTTDP1ALDH1A1
SCHEMBL25952508 0.89 ABCB1 (0.57) ABCB1KCNA3MAPTTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2023-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE LIPC, PC, CYP27A1 ABCB1 3180/4885KCNA3 4014/4885MAOB 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback